Finasteride Tablet, Film Coated
Product Images NDC 68788-8377

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68788-8377). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Finasteride Tablets Usp 5mg (9ae38bf5 17d7 4af1 922f B3edb1e65392 00)

Finasteride Tablets, USP 5 mg film-coated tablet label from Preferred Pharmaceuticals, Inc. The label includes dosing directions in English and Spanish, with barcode and storage instructions. The manufacturer is listed as Camber Consumer Care. The tablet is described as round, blue, and imprinted with H 37. Safety warnings and lot, batch, and expiration date fields are present but not filled in.*

FDA Label Image

Address.jpg (Address)

FDA Label Image

Address3.jpg (Address3)

FDA Label Image

Figure1.jpg (Figure1)

A line graph comparing the mean change from baseline in response over four years between Finasteride and placebo groups. The x-axis represents time points from baseline through Year 4, while the y-axis shows the mean change with standard error. Two lines show Finasteride consistently reducing the measure more than placebo.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph titled 'Figure 2 Percent of Patients Having Surgery for BPH, Including TURP.' It compares the percent of patients undergoing surgery over a 48-month observation period between Finasteride and placebo groups. The graph shows a lower cumulative surgery rate in the Finasteride group compared to placebo, with detailed event counts and at-risk patient numbers listed for both groups at multiple timepoints.*

FDA Label Image

Figure3.jpg (Figure3)

A line graph depicting the mean percent change from baseline over four years for two groups: placebo and finasteride. The x-axis shows time points (Baseline, Year 1 to Year 4), and the y-axis indicates percent change. The placebo group maintains near baseline levels, while the finasteride group shows a decreasing trend below baseline over time, with sample sizes indicated at each time point.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph depicting the percent of participants with an event over time (years from randomization, up to 5.5 years) for four groups: Placebo, Finasteride, Doxazosin, and Combination. The graph shows the percent event on the y-axis and years on the x-axis, with Placebo having the highest event rate and Combination the lowest.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of finasteride, a pharmacologically active compound represented by its molecular diagram with labeled chemical groups and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.